Treatment Of Diabetes Is Different For Men And Women.
Widely hand-me-down diabetes drugs have particular effects on men's and women's hearts, a rejuvenated study suggests. Researchers examined how three commonly prescribed treatments for type 2 diabetes laid hold of 78 patients who were divided into three groups. One group took metformin alone, the subsequent group took metformin plus rosiglitazone (sold under the maker name Avandia) and the third group took metformin plus Lovaza, a type of fish oil. Metformin reduces blood sugar assembly by the liver and improves insulin sensitivity.
Rosiglitazone also improves insulin consciousness and moves free fatty acids out of the blood. Lovaza lowers blood levels of another classification of fat called triglycerides. The researchers found that the drugs had very several and sometimes opposite effects on the hearts of men and women, even as the drugs controlled blood sugar equally well in both genders. The reading appears in the December issue of the American Journal of Physiology - Heart and Circulatory Physiology.
Showing posts with label metformin. Show all posts
Showing posts with label metformin. Show all posts
Friday 6 December 2019
Monday 11 September 2017
Sulfonylurea Drugs Increase The Risk Of Heart Disease
Sulfonylurea Drugs Increase The Risk Of Heart Disease.
New examine shows that older hoi polloi with type 2 diabetes who take drugs known as sulfonylureas to discredit their blood sugar levels may face a higher risk for heart problems than their counterparts who consider metformin. Of the more than 8500 people aged 65 or older with variety 2 diabetes who were enrolled in the trial, 12,4 percent of those given a sulfonylurea drug experienced a fundamentals attack or other cardiovascular event, compared with 10,4 percent of those who were started on metformin. In addition, these pump problems occurred earlier in the course of treatment among those people taking the sulfonylurea drugs, the learning showed.
The head-to-head comparison trial is slated to be presented Saturday at the American Diabetes Association annual convergence in San Diego. Because the findings are being reported at a medical meeting, they should be considered opening until published in a peer-reviewed journal. With type 2 diabetes, the body either does not compose enough of the hormone insulin or doesn't use the insulin it does produce properly.
In either case, the insulin can't do its job, which is to resign glucose (blood sugar) to the body's cells. As a result, glucose builds up in the blood and can exercise havoc on the body. Metformin and sulfonylurea drugs - the latter a form of diabetes drugs including glyburide, glipizide, chlorpropamide, tolbutamide and tolazamide - are often to each the first medications prescribed to lower blood sugar levels in people with type 2 diabetes.
The findings are important, the researchers noted, partly because sulfonylurea drugs are commonly prescribed amongst the superannuated to lower blood glucose levels. In addition, cardiovascular sickness is the leading cause of death among people with type 2 diabetes. For several reasons, however, the original study on these medications is far from the final word on the issue.
For one, people who are started on the sulfonylureas a substitute of metformin are often sicker to begin with, said Dr Spyros G Mezitis, an endocrinologist at Lenox Hill Hospital in New York City. Metformin cannot be prescribed to grass roots with unerring kidney and heart problems. Both medications lower blood glucose levels, but go about it in totally different ways.
New examine shows that older hoi polloi with type 2 diabetes who take drugs known as sulfonylureas to discredit their blood sugar levels may face a higher risk for heart problems than their counterparts who consider metformin. Of the more than 8500 people aged 65 or older with variety 2 diabetes who were enrolled in the trial, 12,4 percent of those given a sulfonylurea drug experienced a fundamentals attack or other cardiovascular event, compared with 10,4 percent of those who were started on metformin. In addition, these pump problems occurred earlier in the course of treatment among those people taking the sulfonylurea drugs, the learning showed.
The head-to-head comparison trial is slated to be presented Saturday at the American Diabetes Association annual convergence in San Diego. Because the findings are being reported at a medical meeting, they should be considered opening until published in a peer-reviewed journal. With type 2 diabetes, the body either does not compose enough of the hormone insulin or doesn't use the insulin it does produce properly.
In either case, the insulin can't do its job, which is to resign glucose (blood sugar) to the body's cells. As a result, glucose builds up in the blood and can exercise havoc on the body. Metformin and sulfonylurea drugs - the latter a form of diabetes drugs including glyburide, glipizide, chlorpropamide, tolbutamide and tolazamide - are often to each the first medications prescribed to lower blood sugar levels in people with type 2 diabetes.
The findings are important, the researchers noted, partly because sulfonylurea drugs are commonly prescribed amongst the superannuated to lower blood glucose levels. In addition, cardiovascular sickness is the leading cause of death among people with type 2 diabetes. For several reasons, however, the original study on these medications is far from the final word on the issue.
For one, people who are started on the sulfonylureas a substitute of metformin are often sicker to begin with, said Dr Spyros G Mezitis, an endocrinologist at Lenox Hill Hospital in New York City. Metformin cannot be prescribed to grass roots with unerring kidney and heart problems. Both medications lower blood glucose levels, but go about it in totally different ways.
Sunday 12 June 2016
Obesity Getting Younger In The United States
Obesity Getting Younger In The United States.
Obese children who don't have standard 2 diabetes but steal the diabetes drug metformin while improving their intake and exercise habits seem to lose a bit of weight. But it isn't much more weight than kids who only for the lifestyle changes, according to a new review of studies. Some evidence suggests that metformin, in society with lifestyle changes, affects weight loss in obese children. But the drug isn't qualified to result in important reductions in weight, said lead researcher Marian McDonagh.
Childhood embonpoint is a significant health problem in the United States, with nearly 18 percent of kids between 6 and 19 years long-standing classified as obese. Metformin is approved by the US Food and Drug Administration to discuss type 2 diabetes in adults and children over 10 years old, but doctors have reach-me-down it "off-label" to treat obese kids who don't have diabetes, according to background information included in the study.
McDonagh's yoke analyzed 14 clinical trials that included nearly 1000 children between 10 and 16 years old. All were overweight or obese. Based on evidence in adults, substance reductions of 5 percent to 10 percent are needed to decrease the risk of serious condition problems tied to obesity, the researchers said. The additional amount of weight sacrifice among children taking metformin in the review, however, was less than 5 percent on average.
Obese children who don't have standard 2 diabetes but steal the diabetes drug metformin while improving their intake and exercise habits seem to lose a bit of weight. But it isn't much more weight than kids who only for the lifestyle changes, according to a new review of studies. Some evidence suggests that metformin, in society with lifestyle changes, affects weight loss in obese children. But the drug isn't qualified to result in important reductions in weight, said lead researcher Marian McDonagh.
Childhood embonpoint is a significant health problem in the United States, with nearly 18 percent of kids between 6 and 19 years long-standing classified as obese. Metformin is approved by the US Food and Drug Administration to discuss type 2 diabetes in adults and children over 10 years old, but doctors have reach-me-down it "off-label" to treat obese kids who don't have diabetes, according to background information included in the study.
McDonagh's yoke analyzed 14 clinical trials that included nearly 1000 children between 10 and 16 years old. All were overweight or obese. Based on evidence in adults, substance reductions of 5 percent to 10 percent are needed to decrease the risk of serious condition problems tied to obesity, the researchers said. The additional amount of weight sacrifice among children taking metformin in the review, however, was less than 5 percent on average.
Subscribe to:
Posts (Atom)